AANS Virtual 2020: Tumor Bundle

The Tumor Bundle provides current, relevant theory and discussion surrounding tumor in neurosurgery. Get instant access and earn up to 7.25 CME in tumor, while bettering your practice with a wealth of knowledge shared through three courses and 32 presentations included in the bundle. 

Pricing

AANS Member$199
Non-member$279

Courses Included

  • Tumor Session
  • Brain Metastases 2.0: Expert Management Strategies and Challenging Cases
  • Technological Adjuncts for Malignant Brain Tumor Surgery

Spine and Trauma bundles also available.

  • Tumor Session

    Includes Credits

    Designed specifically for the tumor subspecialty, hear the latest from elite faculty and learn new approaches to apply in practice. AANS Member: $49 | Non-member: $79

    image

    Designed specifically for the tumor subspecialty, hear the latest research with key takeaways that help practices update and improve approaches to patient care. The session provides 3.25 CME.

    Pricing

    AANS Member$49
    Non-member$79

    Faculty

    Faculty

    • Zsolt Zador, MD, PhD - Awarded The American Brain Tumor Association Young Investigator Award
    • Addison Barnett, MS - Awarded The Journal of Neuro-Oncology Award
    • Sebastian Ille, MD - Awarded The Brainlab Neurosurgery Award
    • Akiyoshi Ogino, M.D., PhD - Awarded The Leksell Radiosurgery Award
    • David S. Baskin, MD, FAANS, FACS - Awarded The Integra Foundation Award
    • Sakibul Huq - Awarded The Brian D. Silber Award
    • Pablo Valdes Quevedo, MD - Awarded The Ronald L. Bittner Award on Brain Tumor Research
    • Sricharan Gopakumar - Awarded The AANS/CNS Section on Tumors Neuro-Oncology Trainee Award 
    • Siri Sahib Singh Khalsa, MD - Awarded The Louise Eisenhardt Travel Scholorship
    • Nikita Lakomkin
    • Reinier Alvarez
    • Rushikesh Sanjeev Joshi
    • Koray Ozduman, MD, IFAANS
    • Riccardo Serra
    • Veit Stoecklein
    • Daniel Zhang
    • Christopher S. Hong, MD
    • Anudeep Yekula, MD
    • Leo Kim
    • Frank Joseph Attenello III, MD
    • Ashish Shah, MD
    • Florian Scheichel

    Learning Objectives

    After completing this educational activity, participants should be able to:

    • Discuss research updates in tumor neurosurgery
    • Apply updates in tumor neurosurgery to practice

    CME Accreditation

    The AANS designates this internet enduring material activity for a maximum of 3.25 AMA PRA Category 1 Credits™.

    Disclosure Information

    As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), the AANS must ensure balance, independence, objectivity, and scientific rigor in all of its sponsored educational activities. In accordance with the ACCME’s Standards for Commercial Support, the AANS is required to disclose to the activity audience the relevant financial relationships of the planners, faculty and any other individual in a position to control content of this activity.

    Please find the relevant financial relationships disclosed below for all individuals in control of content. All conflicts of interest have been resolved in accordance with ACCME Standards for Commercial Support.

    Name

    Relationship/Company

    Akiyoshi Ogino, M.D., Ph.D.

    Stock Shareholder (purchased direct, i.e. not through Mutual Fund, retirement package, etc.) – Elekta ab

    Board, Trustee, Officer, Leadership position specifically with a neurosurgical or medical-related associated, non-profit or similar entity – Insightec

    Grants/Research Support - Japan society for the promotion of science

    Riccardo Serra

    Consultant Fees - AsclepiX Therapeutics, StemGen, InSightec, Accelerating Combination Therapies, Camden Partners,  LikeMinds, Inc, Galen Robotics, Inc., Nurami Medical

    Planners, faculty and any other individuals in control of content not listed have indicated that they have no relevant financial relationships to disclose for this activity.

    Disclaimer

    The opinions expressed in this educational activity are those of the author and do not necessarily represent the views of the grant provider or the AANS. This educational activity does not endorse one particular type of instrumentation, nor is it intended to dictate an exclusive course of management. It presents one of numerous recognized methods of clinical practice for consideration by physicians for incorporation into their practices. Variations of practice taking into account the needs of the individual patient, resources and limitations unique to the institution or type of practice may be appropriate. Disclosure about patient confidentiality, standards of care or course of management does not imply endorsement or disapproval of products.

    Please Note: It is recognized that the use of non-FDA approved devices is described in some of the published material, but these techniques are often the standard of care and may be of value to the patients served.

    Accreditation Designation

    The AANS is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The AANS designates this internet enduring material activity for a maximum of 3.25 AMA PRA Category 1 Credits.

    Physicians should claim only credit commensurate with the extent of their participation in the activity.

    Term of approval is for three years, beginning from 05/27/2020 until 05/27/2023.

    © 2020 American Association of Neurological Surgeons

  • Brain Metastases 2.0: Expert Management Strategies and Challenging Cases

    Includes Credits

    This online course presents major changes in the management of brain metastases that have occurred in the past decade. AANS Member: Free| Non-member: $49

    Brain metastases are commonly treated as a part of a general neurosurgical practice. Major changes in the management of brain metastases have occurred in the past decade. This webinar covers the management of brain metastases, including:

    • Stereotactic Radiosurgery (SR);
    • Post-SR Metastases;
    • Surgical Resection of BM from Eloquent Cortex;
    • Targeted Therapy; and
    • Case Presentations Discussing Different Management Strategies.

    Pricing

    AANS MemberFree
    Non-member$49.00

    Faculty

    Principal Faculty

    • Jeffrey J. Olson, MD, FAANS
    • Andrew J. Fabiano, MD, FAANS

    Learning Objectives

    Upon completion of this activity, participants should be able to:

    • Describe advanced management strategies for brain metastases, including resection, stereotactic radiosurgery and immune therapy.
    • Describe complex stereotactic radiosurgical planning for large metastases, brainstem metastases and cavities before and after resection.
    • Diagnose and manage post-stereotactic radiosurgery (post-SR) brain metastases. 
    • Describe the advantages and shortcomings of neuroimaging techniques in evaluating post-SR brain metastases.
    • Develop an understanding of the role of corticosteroids, bevacizumab and craniotomy in the treatment of post-SR adverse radiation effect/radiation necrosis.
    • Describe the current literature on the role of immune therapy as a primary treatment for brain metastases. 

    CME Accreditation

    The AANS designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™


    Disclaimer

    The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the AANS. This educational activity does not endorse one particular type of instrumentation, nor is it intended to dictate an exclusive course of management. It presents one of numerous recognized methods of clinical practice for consideration by physicians for incorporation into their practices. Variations of practice taking into account the needs of the individual patient, resources, and limitations unique to the institution or type of practice may be appropriate. Disclosure about patient confidentiality, standards of care, or course of management does not imply endorsement or disapproval of products.

    Please note: It is recognized that the use of non-FDA approved devices is described in some of the published material, but these techniques are often the standard of care and may be of value to the patients we serve.

    Disclosure Information

    As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), the AANS must ensure balance, independence, objectivity, and scientific rigor in all of its sponsored educational activities. In accordance with the ACCME’s Standards for Commercial Support, the AANS is required to disclose to the activity audience the relevant financial relationships of the planners, faculty and any other individual in a position to control content of this activity.

    Please find the relevant financial relationships disclosed below for all individuals in control of content. All conflicts of interest have been resolved in accordance with ACCME Standards for Commercial Support.

    Name

    Relationship/Company

    Jeffrey J. Olson, MD, FAANSConsultant Fees – American Cancer Society
    Andrew J. Fabiano, MD, FAANSGrants/Research Support – Arbor Pharmaceuticals Board, Trustee, Officer, Leadership position - Western New York Epilepsy Association, Operation Backbone

    Planners, faculty and any other individuals in control of content not listed have indicated that they have no relevant financial relationships to disclose for this activity.

    None

    Accreditation

    The AANS is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The AANS designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    This activity was published in 5/19/2020. Credit may be obtained until 5/19/2023.

  • Technological Adjuncts for Malignant Brain Tumor Surgery

    Includes Credits

    Review the latest best practices in malignant brain tumor surgery. AANS Member: $49 | Non-member: $79

    Faculty speak to malignant brain tumor surgery and its technical adjuncts for neurosurgeons in the operating room. Earn 3.0 CME and learn about the strategies for intraoperative diagnosis and imaging, tumor resection, noninvasive catheter-based treatments as well as how to recognize the validity of emerging techniques in intraoperative brain tumor visualization.

    Pricing

    AANS Member$49
    Non-member$79

    Faculty

    Principal Faculty

    • Manish K. Aghi, MD, PhD, FAANS
    • Daniel A. Orringer, MD, FAANS
    • Kaisorn Lee Chaichana, MD, FAANS
    • Michael A. Vogelbaum, MD, PhD, FAANS
    • Constantinos G. Hadjipanayis, MD, PhD, FAANS
    • Francesco DiMeco, MD, IFAANS
    • Andrew E. Sloan, MD, FAANS
    • Alexandra J. Golby, MD, FAANS

    Learning Objectives

    Upon completion of this activity, participants should be able to:

    • Apply technological adjuncts that aid in the intraoperative diagnosis and imaging of malignant brain tumors in the operating room during surgery.
    • Distinguish technological adjuncts that aid in the resection of malignant brain tumors.
    • Demonstrate technological adjuncts that enable noninvasive catheter-based treatments of malignant brain tumors.
    • Appraise technological adjuncts that enable minimally invasive, but complete resection, of malignant brain tumors in the operating room.
    • Recognize the scientific basis and proposed clinical applications of emerging techniques in intraoperative brain tumor visualization. 

    CME Accreditation

    The AANS designates this enduring material for a maximum of 3.0 AMA PRA Category 1 Credits™

    Disclaimer

    The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the AANS. This educational activity does not endorse one particular type of instrumentation, nor is it intended to dictate an exclusive course of management. It presents one of numerous recognized methods of clinical practice for consideration by physicians for incorporation into their practices. Variations of practice taking into account the needs of the individual patient, resources, and limitations unique to the institution or type of practice may be appropriate. Disclosure about patient confidentiality, standards of care, or course of management does not imply endorsement or disapproval of products.

    Please note: It is recognized that the use of non-FDA approved devices is described in some of the published material, but these techniques are often the standard of care and may be of value to the patients we serve.

    Disclosure Information

    As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), the AANS must ensure balance, independence, objectivity, and scientific rigor in all of its sponsored educational activities. In accordance with the ACCME’s Standards for Commercial Support, the AANS is required to disclose to the activity audience the relevant financial relationships of the planners, faculty and any other individual in a position to control content of this activity.

    Please find the relevant financial relationships disclosed below for all individuals in control of content. All conflicts of interest have been resolved in accordance with ACCME Standards for Commercial Support.

    Name

    Relationship/Company

    Daniel A. Orringer, MD, FAANS Consultant Fees – Invenio Imaging, Inc., Stryker     Stock Shareholder (purchased direct) - Invenio Imaging, Inc., Stryker Inc    Board, Trustee, Officer, Leadership position – Stryker Inc
    Michael A. Vogelbaum, MD, PhD, FAANSBoard, Trustee, Officer, Leadership position – Infuseon Therapeutics, Inc. Honorarium – Tocagen, Celgene
    Constantinos G. Hadjipanayis, MD, PhD, FAANSConsultant Fees – Synaptive Inc. Other Financial Support - NX Development Corp
    Francesco DiMeco, MD, IFAANSConsultant Fees – Insightec Board, Trustee, Officer, Leadership position - In.tra Stock Shareholder (purchased direct) – Stemgen
    Andrew E. Sloan, MD, FAANSConsultant Fees – Monteris Inc., Surgical Theatre Inc. Other Financial Support – Monteris, Inc Honorarium – Surgical Theatre Inc. Stock Shareholder (purchased direct) – Surgical Theatre Inc., Merck Pharmaceuticals, Inc. Grants/Research Support – Lentigen Inc., PharmacoKinesis

    Planners, faculty and any other individuals in control of content not listed have indicated that they have no relevant financial relationships to disclose for this activity.

    Manish K. Aghi, MD, PhD, FAANS

    Kaisorn Lee Chaichana, MD, FAANS

    Alexandra J. Golby, MD, FAANS

    Accreditation

    The AANS is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The AANS designates this enduring material for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    This activity was published in 5/19/2020. Credit may be obtained until 5/19/2023.

Disclaimer

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the AANS. This educational activity does not endorse one particular type of instrumentation, nor is it intended to dictate an exclusive course of management. It presents one of numerous recognized methods of clinical practice for consideration by physicians for incorporation into their practices. Variations of practice taking into account the needs of the individual patient, resources, and limitations unique to the institution or type of practice may be appropriate. Disclosure about patient confidentiality, standards of care, or course of management does not imply endorsement or disapproval of products.

Please note: It is recognized that the use of non-FDA approved devices is described in some of the published material, but these techniques are often the standard of care and may be of value to the patients we serve.

Accreditation

The AANS is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The AANS designates this enduring material for a maximum of 7.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity was published in 7/17/2020. Credit may be obtained until 7/17/2023.